HOME > REGULATORY
REGULATORY
- PMDA Raises Caution about Using Factor Xa Inhibitor Xarelto, Citing Risk of Interstitial Pneumonia
February 4, 2014
- Wholesalers Call on Drug Makers to “Flexibly” Revise Invoice Prices
February 3, 2014
- PAFSC Committee Designates OTC PMS Treatment as First “Drug Requiring Guidance”
January 31, 2014
- Medical Fee Cuts Will Start from FY2014 to Improve Delivery Price Settlement Rates: Chuikyo
January 30, 2014
- Wary of Drug Price Negotiations Dragging Out into FY2014, MHLW to Survey Price Agreement Rate in March
January 30, 2014
- 2 Bills Related to the Establishment of a “Japanese NIH” to Be Submitted to the Diet in Early February
January 30, 2014
- 3 Entities Strike Codevelopment Deal for Adult TB Vaccines
January 29, 2014
- Rivaroxaban Under Review for Risk of Interstitial Pneumonia: PMDA
January 29, 2014
- PAFSC’s Second Committee to Review Taiho’s Novel Anticancer Agent on Feb. 3
January 28, 2014
- MHLW Setting Out on Development of iPS Tech-Based Cardiotoxicity Evaluation
January 28, 2014
- PAFSC’s First Committee Supports Approval of Second SGLT-2 Inhibitor Dapagliflozin
January 27, 2014
- FDA Bans Imports from Ranbaxy’s Toansa Plant, Daiichi Sankyo Promises Full Cooperation with FDA
January 27, 2014
- Health Minister Waits for Investigation Results on Novartis Involvement in “Sign” Study
January 27, 2014
- Comprehensive Strategy Proposal for “Japan NIH” Calls for Study on Legislation to Prevent Clinical Research Fraud by Autumn
January 27, 2014
- Expert Groups Call for Early Resumption of Active Recommendation for HPV Vaccines
January 27, 2014
- Regulatory Reform Council Eyes New Special System for Mixed Healthcare
January 24, 2014
- NHI Pricing of Generics Set to Undergo Major Revision to Help MHLW Achieve New Target; Promotion through Medical Fee Revision Also Planned
January 24, 2014
- DPP-4 Inhibitors, Remicade to Face Market Expansion Re-Pricing in FY2014 Revision
January 23, 2014
- Chuikyo OKs New NHI Drug Pricing Rules for FY2014 Revision
January 23, 2014
- Gov’t to Fully Implement Japan Version of “Compassionate Use” System in FY2015
January 23, 2014
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…